[CAS NO. ] Zilovertamab

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS

Catalog

HY-P99201

Brand

MCE

CAS

-

DESCRIPTION

Overview

MDL	-
Molecular Weight	-
Molecular Formula	-
SMILES	[Zilovertamab]

For research use only. We do not sell to patients.

Summary

Zilovertamab (UC-961) is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling ^[1] .

In Vitro

Zilovertamab (25 and 50 µg/mL; 72 h) inhibits high-grade serous ovarian cancer (HGSOC) cell proliferation ^[1] .
Zilovertamab (50 µg/mL; 72 h) down-regulates ROR1 expression levels in CaOV3 at the transcriptional level ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay ^[1]

Cell Line:	CaOV3, CaOV3CisR, PEO1, and PEO4 cells
Concentration:	25 and 50 µg/mL
Incubation Time:	72 hours
Result:	Reduced the proliferation of CaOV3, CaOV3CisR and PEO1.

Western Blot Analysis ^[1]

Cell Line:	CaOV3, CaOV3CisR, PEO1, and PEO4 cells
Concentration:	50 µg/mL
Incubation Time:	72 hours
Result:	Down-regulated ROR1 expression levels in CaOV3 at the transcriptional level.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT05458297	Merck Sharp & Dohme LLC	Chronic Lymphocytic Leukemia\|Mantle Cell Lymphoma\|Follicular Lymphoma\|Richter Transformation Lymphoma	July 21, 2022	Phase 2
NCT04501939	University of California, San Diego\|Oncternal Therapeutics, Inc	Chronic Lymphocytic Leukemia	August 6, 2020	Phase 2
NCT02860676	University of California, San Diego	Chronic Lymphocytic Leukemia	November 3, 2016	Phase 1
NCT05139017	Merck Sharp & Dohme LLC	DLBCL\|Diffuse Large B-Cell Lymphoma	January 14, 2022	Phase 2\|Phase 3
NCT02776917	Barbara Parker, MD\|Oncternal Therapeutics, Inc\|University of California, San Diego	Breast Neoplasms	August 15, 2018	Phase 1
NCT02222688	Thomas Kipps\|University of California, San Diego	Chronic Lymphocytic Leukemia	August 8, 2014	Phase 1
NCT03088878	Oncternal Therapeutics, Inc\|California Institute for Regenerative Medicine (CIRM)\|University of California, San Diego\|Pharmacyclics LLC.	B-cell Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma\|Mantle Cell Lymphoma\|Marginal Zone Lymphoma	January 3, 2018	Phase 1\|Phase 2
NCT05562830	Merck Sharp & Dohme LLC	Urothelial Carcinoma	November 15, 2022	Phase 1\|Phase 2
NCT05431179	Oncternal Therapeutics, Inc\|Pharmacyclics LLC.	Lymphoma, Mantle-Cell\|Lymphoma\|Lymphoproliferative Disorders\|Lymphatic Diseases\|Immunoproliferative Disorders\|Immune System Diseases\|Lymphoma, Non-Hodgkin\|Lymphoma, B-Cell	September 2022	Phase 3
NCT03833180	VelosBio Inc.	Chronic Lymphocytic Leukemia\|Mantle Cell Lymphoma\|Follicular Lymphoma\|Marginal Zone Lymphoma\|Diffuse Large B-cell Lymphoma\|Richter Transformation Lymphoma\|Burkitt Lymphoma\|Lymphoplasmacytoid Lymphoma\|T-cell Non-Hodgkin Lymphoma\|Acute Lymphoid Leukemia\|Acute Myeloid Leukemia\|Waldenstrom Macroglobulinemia	March 14, 2019	Phase 1
NCT05156905	University of California, San Diego	Metastatic Castration-resistant Prostate Cancer	June 16, 2022	Phase 1
NCT05406401	Merck Sharp & Dohme LLC	Lymphoma, Large B-Cell, Diffuse (DLBCL)	July 14, 2022	Phase 2
NCT04504916	VelosBio Inc.	Triple-negative Breast Cancer\|Non-squamous Non-small-cell Lung Cancer\|NSCLC\|Estrogen-receptor-positive Breast Cancer\|Progesterone-receptor-positive Breast Cancer\|Estrogen-receptor-negative Breast Cancer\|ER-negative Breast Cancer\|Progesterone-receptor Negative Breast Cancer\|PR-negative Breast Cancer\|HER2-negative Breast Cancer\|ER-positive Breast Cancer\|PR-positive Breast Cancer\|Platinum-resistant Ovarian Cancer\|Gastric Cancer\|Pancreatic Cancer	October 7, 2020	Phase 2

Appearance

Liquid

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References

[1] Liu D, et, al. The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells. Pharmaceutics. 2022 Apr 11;14(4):837.